Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -365.43% is 169% below its 4-year average of -135.79%, around the middle of its 4-year range (-574.11%–-2.88%).
As of the fiscal period ended Tuesday, March 31, 2026. 7.66% below its 12-month average of -339.43%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -365.43%.
RETURN ON EQUITY (ROE)
-365.43%
RETURN ON EQUITY (ROE) AVG TTM
-339.43%
RETURN ON EQUITY (ROE) AVG 3Y
-133.16%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.66%
CURRENT VS 3Y AVG
-174.42%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.94%
median of 451 covered companies
CURRENT VS SECTOR MEDIAN
-863.18%
vs the sector median at left
BioRestorative Therapies, Inc.
Market Cap
$3.04M
Return on Equity (ROE)
-365.43%
TTM Avg
-339.43%
3Y Avg
-133.16%
5Y Avg
N/A
Market Cap
$3.12M
Return on Equity (ROE)
N/A
TTM Avg
-236.13%
3Y Avg
-104.67%
5Y Avg
-48.54%
Market Cap
$2.93M
Return on Equity (ROE)
-554.01%
TTM Avg
-109.66%
3Y Avg
1542.76%
5Y Avg
920.25%
Market Cap
$2.75M
Return on Equity (ROE)
-402.92%
TTM Avg
-276.14%
3Y Avg
-197.40%
5Y Avg
-116.89%
Market Cap
$3.35M
Return on Equity (ROE)
-133.43%
TTM Avg
-203.84%
3Y Avg
-174.81%
5Y Avg
-140.61%
Market Cap
$3.36M
Return on Equity (ROE)
-141.90%
TTM Avg
-194.17%
3Y Avg
-143.89%
5Y Avg
-113.05%
Market Cap
$3.37M
Return on Equity (ROE)
-282.13%
TTM Avg
-313.25%
3Y Avg
-153.55%
5Y Avg
-153.55%
Market Cap
$3.39M
Return on Equity (ROE)
N/A
TTM Avg
5741.84%
3Y Avg
2797.55%
5Y Avg
1847.94%
Market Cap
$2.62M
Return on Equity (ROE)
-657.69%
TTM Avg
-358.53%
3Y Avg
-220.37%
5Y Avg
-149.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioRestorative Therapies, Inc. (BRTX) | $3.04M | -365.43% | -339.43% | -133.16% | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.12M | N/A | -236.13% | -104.67% | -48.54% |
| Jaguar Health, Inc. (JAGX)vs › | $2.93M | -554.01% | -109.66% | 1542.76% | 920.25% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.75M | -402.92% | -276.14% | -197.40% | -116.89% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.35M | -133.43% | -203.84% | -174.81% | -140.61% |
| IceCure Medical Ltd (ICCM)vs › | $3.36M | -141.90% | -194.17% | -143.89% | -113.05% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.37M | -282.13% | -313.25% | -153.55% | -153.55% |
| Evogene Ltd. (EVGN)vs › | $3.39M | N/A | 5741.84% | 2797.55% | 1847.94% |
| iSpecimen Inc. (ISPC)vs › | $2.62M | -657.69% | -358.53% | -220.37% | -149.08% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.52M | -391.26% | -355.49% | -474.62% | -295.97% |
ROE
-365.4%
ROA
-238.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -365.43% |
| 2025-09-30 | -574.11% |
| 2025-06-30 | -221.32% |
| 2025-03-31 | -196.85% |
| 2024-12-31 | -105.25% |
| 2024-09-30 | -61.76% |
| 2024-06-30 | -2.88% |
| 2024-03-31 | -13.73% |
| 2023-12-31 | -69.38% |
| 2023-09-30 | -97.16% |
| 2023-06-30 | -176.44% |
| 2023-03-31 | -154.60% |
| 2022-12-31 | -179.73% |
| 2022-09-30 | -203.19% |
| 2022-06-30 | -183.36% |
| 2022-03-31 | -166.03% |
| 2021-12-31 | -205.14% |
